GlycoMimetics, Inc.

NasdaqGM:GLYC 株式レポート

時価総額：US$10.8m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

GlycoMimetics マネジメント

マネジメント 基準チェック /24

GlycoMimetics'の CEO はHarout Semerjianで、 Aug2021年に任命され、 の在任期間は 3.08年です。 の年間総報酬は$ 2.39Mで、 26.7%給与と73.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.039%を直接所有しており、その価値は$ 4.41K 。経営陣と取締役会の平均在任期間はそれぞれ3.1年と8年です。

主要情報

Harout Semerjian

最高経営責任者

US$2.4m

報酬総額

CEO給与比率26.7%
CEO在任期間3.1yrs
CEOの所有権0.04%
経営陣の平均在職期間3.1yrs
取締役会の平均在任期間8yrs

経営陣の近況

Recent updates

We're A Little Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate

Jun 27
We're A Little Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate

GlycoMimetics Can Become A Game Changer In Blood Cancers

Mar 21

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

Mar 20
Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

Jan 30

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

Nov 19
Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?

Jan 30
Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?

Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

Oct 06
Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

GlycoMimetics has a new Chief Medical Officer

Sep 06

GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K

Aug 03

GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely

Jun 04
GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely

GlycoMimetics Positive Data For AML Therapy Increasingly Likely

Mar 16

Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Nov 20
Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

Aug 20
We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study

May 26

Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

May 12
Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

GlycoMimetics EPS beats by $0.04

May 03

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Mar 26
Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares

Feb 19
GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares

GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings

Jan 24
GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings

How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?

Dec 28
How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?

New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease

Dec 07

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Dec 07
Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

The Investment Case For GlycoMimetics

Nov 17

CEO報酬分析

GlycoMimetics の収益と比較して、Harout Semerjian の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$39m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$2mUS$638k

-US$37m

Sep 30 2023n/an/a

-US$38m

Jun 30 2023n/an/a

-US$37m

Mar 31 2023n/an/a

-US$42m

Dec 31 2022US$1mUS$614k

-US$47m

Sep 30 2022n/an/a

-US$54m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$64m

Dec 31 2021US$3mUS$244k

-US$63m

報酬と市場: Haroutの 総報酬 ($USD 2.39M ) は、 US市場 ($USD 673.68K ) の同規模の企業の平均を上回っています。

報酬と収益: Haroutの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Harout Semerjian (54 yo)

3.1yrs

在職期間

US$2,389,418

報酬

Mr. Harout Semerjian serves as Chief Executive Officer, President & Director of GlycoMimetics, Inc., since August 6, 2021. He served as President and Chief Executive Officer of Immunomedics Inc. since Apri...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Harout Semerjian
CEO, President & Director3.1yrsUS$2.39m0.039%
$ 4.2k
Rachel King
Co-Founder & Director21.7yrsUS$96.00k0.98%
$ 106.1k
Brian Hahn
Senior VP & CFO12.7yrsUS$1.30m0.096%
$ 10.4k
Edwin Rock
Senior VP & Chief Medical Officer2yrsUS$1.15m1.06%
$ 113.6k
Stephanie Irish
Vice President of Accounting5.7yrsデータなしデータなし
Christian Dinneen-Long
General Counsel & Company Secretary5.4yrsデータなしデータなし
Bruce Johnson
Senior VP & Chief Commercial Officer2.6yrsデータなし0.22%
$ 23.2k
Chinmaya Rath
Senior VP & Chief Business Officer1.6yrsデータなし0.25%
$ 26.9k
Shantha Tyavanagimatt
Senior Vice President of Technical Operationsless than a yearデータなしデータなし

3.1yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: GLYCの経営陣は 経験豊富 であると考えられます ( 2.8年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Harout Semerjian
CEO, President & Director3.1yrsUS$2.39m0.039%
$ 4.2k
Rachel King
Co-Founder & Director21.7yrsUS$96.00k0.98%
$ 106.1k
Daniel Junius
Independent Director8.5yrsUS$118.50k0.15%
$ 16.4k
Timothy Pearson
Independent Chairman of the Board10.5yrsUS$138.00k0.038%
$ 4.1k
Scott Koenig
Independent Director7.5yrsUS$100.50k0.057%
$ 6.1k
Scott Jackson
Independent Director5.8yrsUS$111.00k0.0081%
$ 876.6
Patricia S. Andrews
Independent Director7.3yrsUS$105.00k0.091%
$ 9.8k
Mark A. Goldberg
Independent Director10.2yrsUS$111.00kデータなし

8.0yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: GLYCの 取締役会 は 経験豊富 であると考えられます ( 7.8年の平均在任期間)。